Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-amplified Biliary Tract Cancers”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Testing effectiveness (Phase 2)WithdrawnNCT05041972
What this trial is testing

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

Who this might be right for
HER2 Mutation-Related TumorsHER2 Amplified Solid Tumors
Ambrx, Inc.
Testing effectiveness (Phase 2)UnknownNCT06413745
What this trial is testing

Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

Who this might be right for
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd. 65
Testing effectiveness (Phase 2)Study completedNCT04466891
What this trial is testing

ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

Who this might be right for
HER2-amplified Biliary Tract Cancers
Jazz Pharmaceuticals 87
Testing effectiveness (Phase 2)Active Not RecruitingNCT04482309
What this trial is testing

T-DXd in Patients With Selected HER2 Expressing Tumors

Who this might be right for
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca 477
Early research (Phase 1)Study completedNCT00031681
What this trial is testing

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Who this might be right for
Advanced Adult Primary Liver CancerCarcinoma of the AppendixEstrogen Receptor-negative Breast Cancer+85 more
National Cancer Institute (NCI) 41